Literature DB >> 20833283

Neoadjuvant chemotherapy in advanced ovarian cancer: what kind of evidence is needed to convince US gynaecological oncologists?

Ignace Vergote, Frederic Amant, Karin Leunen.   

Abstract

Entities:  

Mesh：

Year:  2010        PMID： 20833283     DOI： 10.1016/j.ygyno.2010.08.011

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN： 0090-8258            Impact factor:   5.482


× No keyword cloud information.
  11 in total

1.  Major clinical research advances in gynecologic cancer in 2010.

Authors:  Dong Hoon Suh; Jae Weon Kim; Kidong Kim; Soon-Beom Kang
Journal:  J Gynecol Oncol       Date:  2010-12-31       Impact factor: 4.401

2.  Hyperthermic intraperitoneal chemoperfusion as a component of multimodality therapy for ovarian and primary peritoneal cancer.

Authors:  Deepa Magge; Lekshmi Ramalingam; Yongli Shuai; Robert P Edwards; James F Pingpank; Steven S Ahrendt; Matthew P Holtzman; Herbert J Zeh; David L Bartlett; Haroon A Choudry
Journal:  J Surg Oncol       Date:  2017-06-19       Impact factor: 3.454

3.  Economic Analysis of Neoadjuvant Chemotherapy Versus Primary Debulking Surgery for Advanced Epithelial Ovarian Cancer Using an Aggressive Surgical Paradigm.

Authors:  Ashley L Cole; Emma L Barber; Anagha Gogate; Arthur-Quan Tran; Stephanie B Wheeler
Journal:  Int J Gynecol Cancer       Date:  2018-07       Impact factor: 3.437

4.  Comparative effectiveness research in gynecologic oncology.

Authors:  Sonali Patankar; Ana I Tergas; Jason D Wright
Journal:  Cancer Treat Res       Date:  2015

Review 5.  Review of methodological challenges in comparing the effectiveness of neoadjuvant chemotherapy versus primary debulking surgery for advanced ovarian cancer in the United States.

Authors:  Ashley L Cole; Anna E Austin; Ryan P Hickson; Matthew S Dixon; Emma L Barber
Journal:  Cancer Epidemiol       Date:  2018-05-25       Impact factor: 2.984

6.  Does the method of primary treatment affect the pattern of first recurrence in high-grade serous ovarian cancer?

Authors:  Yuki Himoto; Paulina Cybulska; Fuki Shitano; Evis Sala; Junting Zheng; Marinela Capanu; Stephanie Nougaret; Ines Nikolovski; Hebert A Vargas; Wei Wang; Jennifer J Mueller; Dennis S Chi; Yulia Lakhman
Journal:  Gynecol Oncol       Date:  2019-09-12       Impact factor: 5.482

7.  Update on first-line treatment of advanced ovarian carcinoma.

Authors:  Z Kemp; Ja Ledermann
Journal:  Int J Womens Health       Date:  2013-01-25

8.  Ascites regression following neoadjuvant chemotherapy in prediction of treatment outcome among stage IIIc to IV high-grade serous ovarian cancer.

Authors:  Xia Xu; Fei Deng; Mengmeng Lv; Binhui Ren; Wenwen Guo; Xiaoxiang Chen
Journal:  J Ovarian Res       Date:  2016-12-02       Impact factor: 4.234

Review 9.  Imaging and therapy of ovarian cancer: clinical application of nanoparticles and future perspectives.

Authors:  Giovanni Di Lorenzo; Giuseppe Ricci; Giovanni Maria Severini; Federico Romano; Stefania Biffi
Journal:  Theranostics       Date:  2018-07-30       Impact factor: 11.556

10.  Anti-cancer therapy and clinical trial considerations for gynecologic oncology patients during the COVID-19 pandemic crisis.

Authors:  Bhavana Pothuri; Angeles Alvarez Secord; Deborah K Armstrong; John Chan; Amanda N Fader; Warner Huh; Joshua Kesterson; Joyce F Liu; Kathleen Moore; Shannon N Westin; R Wendel Naumann
Journal:  Gynecol Oncol       Date:  2020-04-23       Impact factor: 5.482
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.